RUNX2 and acute myeloid leukemia: We then further investigated the metabolic modulation associated with the combined IACS-010759 and AC220 treatment using in-depth metabolic flux analysis (MFA) in two of the wild-type AML cell lines showing strong synergism in the secondary screen (U937 and OCI-AML3).